Skip to content
Review Open access

Advances in targeted delivery and combination immunotherapy of oncolytic viruses for glioma

Oct 2026 · Nano Reseach · 0 citations

Abstract

Glioblastoma (GBM), as the most lethal malignancy of the central nervous system, faces the dual constraints of the physical barrier of the blood-brain barrier (BBB) and a highly immunosuppressive microenvironment, rendering conventional immunotherapies largely ineffective. Oncolytic viruses (OVs), which possess a dual capacity for selective tumor cell lysis and antitumor immunity induction, hold considerable promise for glioma treatment. Nevertheless, the clinical application of OVs remains severely constrained. The constraints include poor intracranial delivery efficiency, swift sequestration by the reticuloendothelial system, and the dampening of therapeutic outcomes. These outcomes are elicited by counter‑regulatory immunosuppressive signals that exist in the microenvironment. This review systematically examines diversified delivery strategies to address delivery challenges. The review also discusses the advantages and limitations of each strategy. Recognizing the suboptimal outcomes associated with single-agent regimens, we further delineate the synergistic interactions across multiple dimensions within combinatorial therapeutic approaches, thus establishing a robust theoretical foundation and proposing practical strategies for clinical translation of OVs-mediated immunotherapy for gliomas. Finally, this review envisions future directions, including personalized combination strategies, safety management, biomarker development, and manufacturing considerations, to inform precision immunotherapy for glioma.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.